DexCom, Inc. (DXCM): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

San Diego, Calif.-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.

A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. DexCom's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.

The company's first product, STS Continuous Glucose Monitoring System, was designed for up to three days of continuous use. This product was removed from the market when DexCom received U.S. Food and Drug Administration (FDA) approval for its second generation continuous glucose monitoring system, SEVEN, named for its design for up to seven days of continuous use. DexCom discontinued sales of SEVEN in the U.S. following the launch of its third generation continuous glucose monitoring system, the SEVEN PLUS, which received approval for up to seven days of continuous use. The company, in Oct 2012, gained approval for its continuous glucose monitoring system, G4 Platinum, and is working on a fifth-generation glucose monitoring system.

In recent times, the company acquired SweetSpot Diabetes Care, an IT organization that creates a cloud-based platform (with 510(k) clearance) dedicated to gathering and dispersing information from diabetes patient devices. Its offering provides automated data collection from patient devices (such as glucose meters) and integration with Electronic Health Record (EHR).

DexCom has collaborative agreements with several companies including Tandem Diabetes Care, Animas Corporation (a subsidiary of Johnson & Johnson) and Edward Lifesciences.